Showing results (581-590 of 1,609) with videos related to

Sort By:
Pageof 161
JAMA Oncology|December 14, 2018
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care SystemSteven D Criss, Meghan J Mooradian, Deirdre F Sheehan, et al.
JAMA Oncology|December 14, 2018
Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A ReviewAllen S Ho, Timothy J Daskivich, Wendy L Sacks, et al.
JAMA Oncology|August 18, 2017
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in MelanomaAlexander N Shoushtari, Claire F Friedman, Pedram Navid-Azarbaijani, et al.
JAMA Oncology|October 28, 2017
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F Seligmann, Ace J Hatch, Susan D Richman, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
JAMA Oncology|January 19, 2018
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk PredictionElke M van Veen, Adam R Brentnall, Helen Byers, et al.
JAMA Oncology|January 13, 2018
Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell CancerRichard B Hayes, Jiyoung Ahn, Xiaozhou Fan, et al.
JAMA Oncology|January 13, 2018
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung CancerYasuo Oshima, Tetsuya Tanimoto, Koichiro Yuji, et al.
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
JAMA Oncology|May 19, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical TrialJens-Uwe Blohmer, Theresa Link, Mattea Reinisch, et al.
Pageof 161